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ET-1 (endothelial-1), a peptide hormone, is a potent vasoconstrictor that 
contributes to the increased expression of oncogenes (1). ET-1 shows increased 
expression in normal male human ejaculate and has a strong association with metastatic 
prostate cancer. It has been shown that ET-1 directly induces prostate cancer and 
increases the mitogenic effects of insulin-like growth factor I, insulin-like growth factor 
II, platelet-derived growth factor, basic fibroblast growth factor, and epidermal growth 
factor in serum-free conditions in vitro. ET-1 expression is increased under the 
environment of ischemia and hypoxia since there is a hypoxia-inducible factor-1 (HIF-1) 
binding site in the human ET-1 promotor (3). The HIF-1 binding site contributes to the 
activation of ET-1 expression in endothelial cells. The conditions of hypoxia are not 
solely contributed to HIF-1 but 50 base pairs of flanking sequence for the binding sites of 
activator protein (AP-1), proliferation factor (GATA-2), and CAAT-binding factor (NF-
1). Previous experimentation shows mutations at the HIF-1 site eliminated hypoxia 
induction but mutations at GATA-2 caused the over expression of GATA-2. GATA-2 
must be studied in other models to see if it will increase the expression of oncogenes in 
tumor proliferation (6).  
 I’m studying to see if GATA-2 will act as a proliferation factor in a prostate 
cancer model. LNCAP is a known prostate cancer cell lie that is chosen for its androgen 
dependent behavior. In a biochemical setting the question is asked if the decreased 
expression of GATA-2 affect the growth rate of LNCAP cells (2). To find the answer to 
this question small interference RNA (siRNA) sequence targeted specifically to GATA-2 
was used to decrease the expression GATA-2 in LNCAP cells. siRNA was introduced 
into LNCAP cells in lipofectamine transfection. The authenticity of the siRNA as a 
mechanism for RNA interference to decrease GATA-2 expression was verified with the 
use of Western Blotting and Real-time PCR (RT-PCR) analysis. After the verification of 
the siRNA function, LNCAP cells were transfected with the siRNA. Later LNCAP cell 
counts were taken with siRNA and without siRNA. LNCAP cell counts increased in 
control groups as compared to those transfected, which demonstrates GATA-2 as a 
proliferation factor for LNCAP cells. Further experiments should find where in the cell 
cycle GATA-2 affects proliferation factors and in vivo murine studies should later be 
examined. In previous studies GATA-2 is a proliferation in cancer models that have 
androgen dependent behavior. If GATA-2 can be proven as a proliferation factor in 
LNCAP, this will give greater understanding for its role in cancer models. 
In a clinical prostate cancer research setting, I’m working to gather data for 
possible SNP (single nucleotide polymorphism) of up-regulated FGF (fibroblast growth 
factor) genes. SNP is a change in one nucleotide from an exon sequence, which can lead 
to translation of a different protein (5). It has been shown in previous studies there is 
increased occurrence of SNP in cancerous tissue as compared to noncancerous tissue. 
The SNP study was initially based upon microarray data to show possible genes of high 
interest. These genes under my study were hOGGI and 136. The SNP for the change of 
the nucleotide G to a C leads to a formation of serine for threonine (4). The genotyping of 
136 and hOGGI shows there is a statistical significance in SNP occurrence for just 136. 
The possible roles that 136 plays must be looked upon for further prostate cancer studies. 
From previous literature, 136 has a universal role as a SNP in other cancerous diseases 
such as esophageal cancer (7). Since the control SNP of hOGGI is already known we can 
just compare the cancer SNP to the literature SNP counts.  
Prostate cancer is one of the leading causes of death of men. Fibroblast growth 
factor (FGF) signaling is important as it is expressed at increased levels in men with 
prostate cancer (4). The expression of FGF can play a role in the functions of cell 
motility, proliferation, and the increase in tumor angiogenesis. Intracellular acidic 
fibroblast growth factor binding protein (FIBP) is believed to have a strong association 
with acidic FGF (aFGF) to activate a multitude level of responses (6). Acidic FGF has 
both an extracellular and intracellular function. The extracellular behavior involves it 
binding to fibroblast growth factor receptors (FGFRs) on the cell membrane. There are 
four transmembrane tryosine-kinase receptors that potentially play a role in prostate 
tumor progression. The binding of aFGF to FGFRs leads to the cross linking of the 
receptors to activate tyrosine-kinase domain, which can activate several intracellular 
phosphorylation cascades (1). The role of FIBP remains unclear as it moves possibly 
from the nucleus to the cytoplasm. It is postulated that FIBP is not involved in the 
transport aFGF into the nucleus but rather it binds to aFGF to activate DNA synthesis. 
The binding of FIBP to aFGF appears to be electrostatic in nature and the binding seems 
to be inhibited in the presence of heparin. The expression of FIBP appears to play an 
essential role in the aftermath of it binding to aFGF in the nucleus region (6). Because 
FGF signaling is essential in prostate cancer, I investigated the expression of FIBP in 
human prostate benign tissues and human prostate cancer tissues to ascertain whether 
there is differential expression of FIBP in human prostate cancer tissues. Previous studies 
show FGF being up-regulated in the prostate cancer lines versus normal cell lines. Since 
FGF is established as a possible for the tumor proliferation in prostate cancer to 
understand the role binding factors such as FIBP play with FGF will further elucidate the 
complete mechanism of FGF.  
 
Materials and Methods:  
 
hOGGI and 136 Genotyping: To determine the distribution of SNP for hOGGI 
and 136 in prostate cancer patients and in control groups, the following primers were 
used: 5’-CCTCTTGGACCTTAGATGCTTC-3’ and 5’-CTGGACAGCGGAACTTGAC-
3’ (137F/137R) and 5’- GGGGATTATTTTATTTTCTATG-3’ and 5’-
AGCAGAGGGAGAGCTTCTG-3’ (hOGGIF/hOGGIR). The PCR product from a 1.5% 
TAE DNA gel of the primers is 317 bp in length for 136 and 250 bp in length for hOGGI. 
The annealing temperature that was used to generate the PCR products was 68.5C 
following the restriction enzyme digest. The C to G change in one nucleotide leads to 
change in protein of serine to threonine. A restriction enzyme digest at 37C for 4 hours of 
the PCR products was performed with EcoNI for 137 and FNUHI  
for hOGGI. This verified the presence of our SNP under analysis. 
Construction of FIBP plasmid standard: Oligonucleotide primers were 
designed as FIBPC25 forward (5’-ACCAGTGAGCTGGACATCTTCG-3’) and 
FIBPCR15 reverse (5’-GGGAGTGGACAGACGCTGAAT-3’) to amplify a 987 bp 
fragment encompassing the FIBP cDNA in a PCR reaction. A standard PCR reaction was 
carried out using LNCAP cDNA as template in a reaction containing 0.4µM of the 
forward and reverse primers and the following conditions (initial denaturing at 95
o
C for 3 
minute, followed by 34 cycles of denaturing at 95
o
C for 30 seconds, annealing at 60
o
C 
for 30 seconds and extension at 70
o
C for 1 minute and a final extension at 72
o
C for 7 
minutes).   The PCR reaction was analyzed by gel electrophoresis on 1% agarose gel and 
the 987 bp fragment purified from the gel using Qiagen gel purification kit (and 
according to the manufacturer’s protocol). The 987 bp cDNA fragment was subsequently 
cloned into Topo Vector (Invitrogen; and according to the manufacturer’s protocol) and 
the recombinant plasmid DNA was prepared using a Qiagen kit and verified by EcoRI 
restriction enzyme digestion. 
Quantification of plasmid was performed spectrophotometrically. The measurements of 
the plasmid concentration were done in duplicate and then converted to copy number (N). 
N (copy number per µl) = moles X Avogadro constant. 




 copies)   was used for DNA standard. 
Gradient PCR is used for three sets of primers which encompassed the on 987 bp region 
of FIBPC25/FIBCR15 to obtain the primer of least background of non-specific binding at 




C. Primer FIBP 1R/1F which encompasses a 
region of 152 bp of the FIBP gene was chosen at the annealing temperature of 68
 o
C. 
Quantitative Real-time PCR: Quantitative Real-Time PCR (RT-PCR) was performed 
on a  reaction using 5 µl of template cDNA in a total 25 µl reaction volume consisting of  
FIBP forward primer ((5’-GACCATTACCGCACCTTCC-3’) and reverse primer 
(CAGCACCTCCCGAACAAAG) 0.4 µM of each primer, 3mM MgCl2, 2.5 µl of LC-
FastStart DNA Master Sybr Green I (490 nm). RT-PCR was conducted using the iCycler 
instrument (Bio-Rad) with the optimal PCR conditions for FIBP amplification using the 
following: 3 minute hot start at 95
 o
C for 30s, annealing at 68
 o
C for 20s, and a 72
o
C 
extension for 30s. Each of the reactions consisted of a negative control, and the 
experiment was done in duplicate. The fluorescent was given off by the reporter dye 
(Sybr Green I), and the threshold cycle (Ct) of each sample was recorded as a quantitative 
measure of the amount of PCR product of the sample. Then the FIBP copy number was 
normalized against β-actin expression levels in each of the prostate cell lines. N = (RT-
PCR/β-actin N) for each of the select prostate cell lines.   
Results: 
 
Table 1 (The Real-Time expression of GATA-2 siRNA function on LNCAP cells) 
Control (normal) siRNA (transfected) 
1. 24hr normal (10 ul H2O)  
expression=8.78E5 B-actin=9.9E6 
final expression=8.86E-2  
 
1. 24hr (20ul) 200 picmol  
expression=2.44E6 B-actin=4.93E7 
final expression=4.95E-2  
 
2. 48hr normal (10 ul H2O)  
expression=1.19E6 B-actin=2.4E7 
final expression=9E-2  
 
2. 48 hr (10 ul) 100 picmol  
expression=1.44E6 B-actin=1.6e7 
final expression=4.9e-2  
 
3. 72 hr normal (20 ul H2O)  
expression= 1.23E6 B-actin=1.27E7 
final expression=9.66E-2  
 
3. 48 hr (20 ul) 200 pic mol  
expression=9.07E5 B-actin=3.24E7 
final expression=2.799E-2  
4. 72 hr (10 ul) 100 picmol  
expression=5.06E5 B-actin=4.79E6 
final expression=1.05E-1  
 
 5. 72 hr (20ul) 200 picmol  
expression=3.95E5 B-actin=1.65E7 
final expression=2.393E-2  
 
It can be seen at 200 picomol or 20 ul of the siRNA transfection agent there seems to be a 
gradual knockdown of the GATA-2 gene with siRNA. This is going from 24, 48, and 72 
hours from the control to the transfected cell line. 

























Normal Prostate cell line
Transfected prostate cell line
 
Figure 1.1: Shows the graphical representation of Table 1.1. It can be seen that the 
transfected cells had decreased expression of GATA-2 as compared to the control cell 
line over the various time periods.  
 
 
Table 2 (original GATA-2 LNCAP cell counts) 
SiRNA Transfection Control (H2O) 














































































Figure 1.2: Shows a graphical representation of Table 2. It can be seen that as the time 
period increases there is a decrease in the cell counts from the control to the transfected 
cells.  
 
Table 3 (repeat of GATA-2 LNCAP cell counts) 
SiRNA transfection Control (H2O) 


































Day 5 Day 5 


















Both tables 2 and 3 show the GATA-2 LNCAP cells counts for both an original and a 
repeat cell count that is done in an experimental duplication for one, three, and five days. 
The experimental repeat or duplication was done out of necessity so that we could verify 
the results of the experiment without the possibility of experimental error. 200 picomole 
of the siRNA reagant was added to each 35 mm dish.  
 























Figure 1.3: Is a graphical representation of Table 3. It can be seen the cell counts from 
the transfected to the control cells do decrease. Yet, there is concern for the Day 5 cell 
counts since the control and the transfected cells counts both decrease. Part of the 
decrease is attributed to competition between the cells and limited availability of 





Day 1 Day 3 Day 5 
Table 4 (shows the SNP for 100 human cancer samples for hOGGI 
using the restriction enzyme FNUHI) 
 



















































































































































































































Table 5: To investigate the expression of FIBP in benign and cancerous tissues we used  
RT-PCR. We analyzed cDNA consisting of 20 tissues of high recurrence, 20 tissues of 
low recurrence, 19 tissues of non-recurrence, 8 tissues of benign prostate hyperplasia 































  Fig. 1.4: Comparative expression of FIBP amongst cancer and normal prostate 
cells using quantitative RT-PCR. FIBP expression was normalized using β-actin with the 






The Real-Time PCR data in Table 1 shows the various siRNA transfection 
amounts given and demonstrates 200 picomole of siRNA as the optimal reagent needed 
to perform the cell counts on. Results from Table 1 are needed since it verifies the 
optimal condition to use GATA-2 in a lipovectamine transfection to assess its possible 
role as a proliferation factor in LNCAP cells. LNCAP cell counts taken for GATA-2 
show decreased cell counts when siRNA was administered. The siRNA lipovectamine 
transfection decreased the expression of GATA-2 in Table 1 for the Real-Time PCR 
experiment and decreased LNCAP cell counts. The LNCAP cells with siRNA 
transfection reagent were compared to control LNCAP cell counts without siRNA 
reagent. The decreased LNCAP cell counts with siRNA reagent prove that GATA-2 acts 
as a proliferation factor for LNCAP cells. With the importance of GATA-2 as a 
mechanism for the proliferation of the LNCAP cells there comes to question the 
functional role that GATA-2 can play for proliferation. To understand at a greater depth 
the mechanistic approach that GATA-2 plays, one should perform a cell cycle assay to 
determine in which part of the cell cycle that GATA-2 plays an important role. This will 
give greater insight into the precise steps that GATA-2 plays in the proliferation of 
LNCAP cells. Moreover, since it is seen that GATA-2 plays a mechanistic role for 
increased expression we should try to find a better means for its stepwise methodology. 
Furthermore, other experiments must be designed to obtain the mechanistic role of 
GATA-2 as a proliferation factor. Future experiments are now underway to use flow 
cytometry to understand where in the cell cycle GATA-2 increases its expression to 
proliferate prostate cancer cell counts. The biology of GATA-2 can be investigated using 
a murine model to test and understand the exact effects that GATA-2 when there is 
decreased and increased expression. By having a model organism to represent the 
expression profile that GATA-2 plays one can determine its role of regulation within the 
cell as a whole.  
In the investigation of hOGGI, the genotype frequencies were generated from the 
100 human cancer samples; the allele frequencies came out to be 69% CC (Ser/Ser), 27% 
CG (Ser/Cys), 4% GG (Cys/Cys). This data for cancer SNP of hOGGI is in a strong 
correlation to the published data for control of American (Caucasian) males, which were 
75.2% CC (Ser/Ser), 23% CG (Ser/Cys), 4% GG (Cys/Cys). This data shows there is not 
enough significance to claim that there is difference for the allele frequencies of hOGGI 
SNP to occur. The future studies of the hOGGI SNP can still be studied in other cancer 
models to assess if there is difference in the data from the cancer to the control allele 
frequencies.  
 
The increased expression of FIBP in cancerous tissues suggests that FIBP could 
play a possible role in the up regulation of human prostate tumor angiogenesis. There is a 
40% increase in the expression of FIBP in cancer as compared to the normal prostate 
cancer cell line. The expression of FIBP in the prostate cancer cell expression is 
significant enough to determine its importance in the role of the tumor proliferation. 
Due to aFGF intracellular nature, further studies need to be conducted to see the 
expression levels of FIBP in response to aFGF stimulation of normal prostate and 
prostate cancer cells in vitro and also the biological effects of over-expression/down-
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